Vaishali Pharma Limited — Call Transcript 2023

Nov 29, 2023

==> picture [594 x 136] intentionally omitted <==

November 29, 2023

To, The Manager

National Stock Exchange of India Limited

Exchange Plaza, 5[th ] Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

Sub: Transcript of Earning Call pertaining to the Financial Results for the quarter and half year ended September 30, 2023.

We enclose herewith a copy of the transcript of the Earning Call on the Unaudited Financial Results of the Company for the Second quarter and half year ended September 30, 2023 held on Thursday, November 23, 2023.

The same is also being made available on the Company’s website at www.vaishalipharma.com .

Kindly take the same on your records and oblige.

Thanking you.

Yours faithfully, For Vaishali Pharma Limited,

Digitally signed by ATUL ARVIND VASANI DN: c=IN, postalCode=400092, st=MAHARASHTRA, street=MUMBAI, l=MUMBAI, o=Personal, ATUL ARVIND serialNumber=35914012f3e140785bf4249cd5cc73169b6ae32adb4a9dbf0b3e540264d5677d, pseudonym=4577cd45acbd4b81950fdca30f5e447f, 2.5.4.20=747c328d3a1e3225296efcb194cb6551268d2b VASANI 7a972751d8213868e97966fe56, email=ATUL@VAISHALIPHARMA.COM, cn=ATUL ARVIND VASANI Date: 2023.11.29 17:17:02 +05'30'

Atul Arvind Vasani Chairman & Managing Director

Place: Mumbai

==> picture [510 x 40] intentionally omitted <==

==> picture [89 x 81] intentionally omitted <==

“Vaishali Pharma Limited

Q2 FY24 Results Conference Call”

November 23, 2023

==> picture [65 x 58] intentionally omitted <==

==> picture [65 x 66] intentionally omitted <==

==> picture [106 x 53] intentionally omitted <==

– MANAGEMENT: MR. ATUL VASANI CHAIRMAN AND MANAGING

– DIRECTOR VAISHALI PHARMA LIMITED

– – MR. DEWANSH VASANI EXECUTIVE DIRECTOR VAISHALI PHARMA LIMITED

– – MR. RATNESH SINGH CHIEF FINANCIAL OFFICER VAISHALI PHARMA LIMITED

– MODERATOR: MS. CHANDANI CHANDE KIRIN ADVISORS

Page 1 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Moderator:

Ladies and gentlemen, good day and welcome to the Vaishali Pharma Limited Q2 FY24 Results Conference Call, hosted by Kirin Advisors. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded.

I now hand the conference over to Ms. Chandani Chande from Kirin Advisors. Thank you and over to you ma'am.

Chandani Chande:

Thank you. On behalf of Kirin Advisors, I welcome you all to the conference call of Vaishali Pharma Limited. From management team, we have Mr. Atul Vasani, Chairman and Managing Director, Mr. Dewansh Vasani, Executive Director and Mr. Ratnesh Singh, Chief Financial Officer.

Now I hand over the call to Mr. Dewansh Vasani. Over to you, sir.

Dewansh Vasani:

Thank you for that warm welcome. I appreciate the opportunity to address the distinguished participants of this conference call. As we gather to discuss the performance of Vaishali Pharma Limited during the quarter to financial year 24, it's indeed an exciting time to reflect on our achievements and milestones.

Before we dive into the details of our performance, let me provide a brief overview of our company and our business model. Vaishali Pharma Limited, established in 1989 in Mumbai, is a pharmaceutical company that specializes in manufacturing and marketing a diverse range of healthcare products. Our product portfolio includes API, formulation, surgical products, veterinary supplements, herbal items, nutraceuticals and oncological products.

We cater to healthcare needs of both humans and animals. While we have a strong presence in Maharashtra, India, we have also expanded to reach globally through strategic partnerships. Vaishali Pharma Limited has established collaborations in the Democratic Republic of Congo, Kenya and Russia, allowing us to distribute their pharmaceutical products in this region.

One notable partnership involves Sankalp Life Care, a prominent nutraceutical manufacturer. We have entered into a strategic alliance with Sankalp Life Care to manage the marketing operations of Sankalp Life Care products, both domestically and internationally. This collaboration enhances their ability to promote and distribute health supplements produced by Sankalp Life Care on a global scale.

At Vaishali Pharma, our dedicated team is focused on creating various healthcare products, including pharmaceutical formulations, APIs, surgical, veterinary, herbal and nutraceutical products. Our goal is to bring unique value to patients worldwide. With decades of experience in pharmaceutical marketing and exports, we collaborate with multiple manufacturing facilities across India.

Page 2 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Our operations extend to international markets, encompassing formulation, surgical and API manufacturing facilities, ensuring compliance with WHO GMP guidelines. In each manufacturing unit, we have dedicated quality control teams to ensure the high quality of our products. Over the years, we have successfully manufactured and exported more than 250 formulations, specializing in tailor-made healthcare solutions.

We have started working in the nutraceutical product area, and the ongoing collaborations and partnerships are going to be important for our future growth. Our vision at Vaishali Pharma is clear to be recognized as a prominent Indian multinational in the pharmaceutical and healthcare industry. We are driven by a mission to actively contribute to the well-being of society by delivering high-quality products and services.

Our core values include a commitment to total quality management, providing excellent customer support, building enduring trust in business relationships, and demonstrating respect for all individuals. Embedded in our business ethic is the Vaishalian code of conduct, which upholds values such as integrity, customer focus, innovation, passion, productivity, and adaptability. We ensure compliance with the regulatory requirements of different countries, navigating their rules and documentation.

As suppliers of APIs to renowned companies approved by multinationals and major Indian corporations, we offer competitive rates for formulations. The quality of our product is the core of our business. The quality products at competitive rates offer us huge growth opportunities for seeking orders from multinational companies.

Further, our research and innovation will strengthen our position in contract manufacturing. With a well-structured supply chain management system, we consistently deliver on time, fostering substantial growth in our customer base over the years. We are happy to share the results for the H1 Financial Year 2024.

Our success comes from innovative ideas, our high-quality standards, and expanding global reach to important partnerships. Now let me take you through the financial performance in quarter 2 financial year 24 and half yearly financial year 24. The total revenue for H1 financial year 24 stands at INR26.65 crores with a noteworthy EBITDA of INR5.62 crores and an EBITDA margin of 21.11%. We achieved a net profit of INR3.29 crores resulting in a net profit margin of 12.34%.

EPS is reported at INR3.10. For quarter 2 financial year 24, the total income is reported at INR12.86 crores accompanied by a notable EBITDA of INR2.95 crores and a commendable EBITDA margin of 22.97%. Our net profit for this quarter stands at INR1.70 crores resulting in a net profit margin of 13.24%. The EPS is recorded at INR1.61. Our quality product and cost efficiency enabled us to earn such an impressive margin in the reported year.

Going forward, we are optimistic about EBITDA margins with upward bias. In the end, I want to express sincere gratitude to all our stakeholders for playing a crucial role in our journey of growth. Your support and faith played a pivotal role in our success.

Page 3 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Now, I welcome you to share any questions or thoughts you may have. Thank you once again for your presence and continued support.

Moderator:	Thank you so much. We will now begin the question and answer session. The first question is
	from the line of Prakash Jaiswal from Shree Capital. Please go ahead.
Prakash Jaiswal:	Hello, good afternoon sir. Thanks for the opportunity. Sir, we have the presence of 35 plus
	location and exports to various countries. So, how does company planning to further expand its
	market reach?
Atul Vasani:	We are exploring into 45 to 46 countries. We are in under process for exploring, registration is
	going on. In coming next one or two year will start in those countries.
Prakash Jaiswal:	Okay, sir how will be your domestic and international sales contribution?
Atul Vasani:	40:60.
Prakash Jaiswal:	40:60?
Atul Vasani:	Yes.
Prakash Jaiswal:	Okay. And sir, are there any identified risk or challenges in the industry that company is
	actively addressing?
Atul Vasani:	Sir, we have worldwide challenges in many places. We are in Myanmar, Lebanon, Russia. But
	sir, there are so many countries and we don't have a lot of weightage. So, there are not many
	problems.
Prakash Jaiswal:	Okay. And sir, any specific milestone or goal company aims to achieve near term in future?
Atul Vasani:	Sir, we have a plan to reach INR400 crores to INR500 crores in the next 5 years.
Prakash Jaiswal:	Okay. And sir, can you provide insight on specific goal and growth exception from the
	strategic alliance with the Sankalp Life Care?
Dewansh Vasani:	Sir, the tie-up with Sankalp is very good. Sankalp is a USFDA approved plant. And its
	nutraceutical range is accepted worldwide. And the total marketing of Sankalp and export is
	under Vaishali Pharma. And it is increasing day by day. We are getting approvals from
	everywhere. Now, sir, our material has been approved in the UK. It has been sent to the US.
	Approval is coming from there. Gradually, sir, it is increasing. And the strategic alliance that
	you can tell, the partnership, will be at a new level in the coming years.
Prakash Jaiswal:	Okay. And sir, any specific capex you are looking for in the near term?
Dewansh Vasani:	Capex? Not in the near term, sir. But we can say within 2-3 years, we will be looking out to
	acquire a factory.
Prakash Jaiswal:	Okay. Like inorganic growth?

Page 4 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Dewansh Vasani: Yes.

Moderator:

Thank you so much. The next question is from the line of Chinmay Rane from Kojin Finvest. Please go ahead.

Chinmay Rane: Yes, thank you for the opportunity. Sir, you just mentioned that in the next 3-4 years, your target is to reach the INR500 crores of revenue. So, what are the strategies you are looking for? So, any product pipeline, any tie-ups, any acquisition, what are the strategies to achieve those kind of a target which you are looking at? Atul Vasani: Madam now about 350 products are registered. And near about 200 more products are in registration within one year. We get the results after at least three years. So, the way we are doing it, it seems like everything will happen automatically. And we have started putting up tenders as well. So, the volume of the tenders is very big.

	So now we feel that down the line, we will start some tenders, but the rest of our products, the
	ones we are continuously putting in, the ones we are putting in as a system, the results are also
	starting to come.
Chinmay Rane:	Okay. Sir, we have submitted this tender today in a domestic country or where?
Atul Vasani:	Madam, can you please come again?
Chinmay Rane:	Where have we submitted the tender you are talking about?
Atul Vasani:	International.
Chinmay Rane:	International.
Atul Vasani:	Africa, Europe.
Chinmay Rane:	Government hospitals?
Atul Vasani:	Yes.
Chinmay Rane:	Sir, API and all those streams – various verticals we presence, among these what diseases do
	we target?
Atul Vasani:	Madam, can you repeat?
Chinmay Rane:	We have so many verticals presence in, so what diseases do we target? All of them?
Atul Vasani:	Yes, Antibiotics, diabetes, anti-cancer, we mainly target antibiotics. We have a strong
	antibiotics.
Chinmay Rane:	And the tie-up with Sankalp, mainly is a marketing tie-up? Right?
Atul Vasani:	Yes, it is a marketing tie-up.

Page 5 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Chinmay Rane: So will you sell it in our brand or how is it?

Atul Vasani:

Atul Vasani: We are selling it in Vaishali Pharma's brand. Chinmay Rane: We have a lot of products in development. What are the teams of our research? Atul Vasani: We have 6 people in the regulatory. And I have a technical officer who is a senior. And he is handling everything.

Chinmay Rane: Are we trying to enter the United Nations? Atul Vasani: In United Nation only nutraceuticals in Pharma. We are continuing with nutraceuticals. Chinmay Rane: And how much does it contribute to your total revenue? Atul Vasani: No, it hasn't happened yet. Chinmay Rane: Okay, it hasn't happened yet. And you said around 350 to 375 products are in pipeline? Atul Vasani: Yes. Chinmay Rane: And that will be launched in the next 2-3 years? Atul Vasani: Yes. Moderator: Thank you. The next question is from the line of Ankit Kumar, who is an individual investor. Please go ahead. Ankit Kumar: Yes. So, my question is, considering the financial results for H1 FY ‘24, what factors contributed to the notable EBITDA margin of 21.11% and the net profit margin of 12.34%? Dewansh Vasani: Yes. Sir, can you repeat your question?

Ankit Kumar: Yes. So, actually, the EBITDA margin and the net profit margin of 21.11% and 12.34%, what factors contributed to this?

Dewansh Vasani: Sir, for us, it has the contribution of APIs, surgical, and the main contribution is the formulation products. And because of this, we have come to this EBITDA. And as I told you in my opening speech, sir, it will gradually increase and it will be very good. Ankit Kumar: Okay, sir. So, this margin level, is it maintainable or will it increase in the future more?

Dewansh Vasani: Sir, it is sustainable and it will increase. Sir, how does it work? There is a brand value. At a stage, the brand develops. Then the EBITDA margin increases instead of decreasing. This is the difference between normal trading and self-branding. We have our own brand, sir. So, it increases in that brand.

Ankit Kumar: Okay, sir. So, what specific initiatives are you going to take in the future to gain the sustainability?

Page 6 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Dewansh Vasani: Sir, we are still taking the steps and we are going to take them in the future to gain the sustainability. Sir, the major factor is the timely delivery, according to which we get repeat orders of the same product. And apart from that, we also do promotions in those countries where we export. We also sell promotional materials there to create awareness and to increase our market share in those regions. Ankit Kumar: Okay. Thank you, sir. Dewansh Vasani: Thank you. Moderator: Thank you so much. The next question is from the line of Ketan Athavale from Robo Capital. Please go ahead. Ketan Athavale: Hello, sir. Thank you for the opportunity. Firstly, I wanted to know that in the latest quarter and FY ‘23, how much is our split revenue from manufacturing and marketing? Dewansh Vasani: What question you asked, sir? From manufacturing and? From marketing activities, sir. What is the split revenue? Okay, from manufacturing and trading. Sir, you can calculate the ratio here that it can be almost 50%-50%. It can be 50%-50%. Ketan Athavale: 50% of revenue is from manufacturing and the rest is from marketing. Dewansh Vasani: Yes. Ketan Athavale: This is for FY ‘23 or Q2 FY ‘24? Dewansh Vasani: Sir, we have done for Q2 FY24 and now, we are on the same line. And gradually, we will go to 60%-40%. We will turn it to 60%-40%. This is our try. 10 years ago, we were only in marketing. Gradually, we came to manufacturing. And gradually, our company's share has come to 50%-50% level. And gradually, we are increasing the share of manufacturing side. And in the marketing side, it is gradually increasing. Ketan Athavale: Okay. So, till when is this 60% achievable? Dewansh Vasani: Sir, you can say very soon. And we are going towards that. Maybe, this can be achieved in the next H2. Or you can say it can be achieved in the first quarter of next year. Ketan Athavale: Okay. In February, we got an order of INR600 crores. Which you had put a notice in NSE. Was that basically a marketing order or? Dewansh Vasani: No, sir. It is an export order. That is also a tender, sir. We have already got that tender. In that tender, our condition is of advance payment. And there is a problem in the international market. For that, it is stuck. We are still continuing the paperwork. And we are working on it. Ketan Athavale: Okay. So, how much clarity can we get? And how much will that INR600 crores contribute to your revenue?

Page 7 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Dewansh Vasani:

Sir, the entire style of the company will change. It is a big order. For a company, if a company with a channel of INR80 crores-INR90 crores gets an order of INR600 crores, it is a big, very big achievement.

Ketan Athavale:

Exactly. So, basically, from where can you get it? Can you give us some guidance?

Dewansh Vasani: Sir, in export, sometimes the order is clicked in six months-eight months. Sometimes, it takes three years-four years. We feel that there are chances in the next six months. And we continue to implement whatever happens in the board.

Ketan Athavale: Yes. Sure. Okay. And you have given a guidance of INR400 crores-INR500 crores in the next three years-four years. So, what will be the immediate term guidance in FY ‘24 and FY ‘25?

Dewansh Vasani: Sir, we are going with an 18%-20% growth. If suddenly a big order comes, then it is a different matter. Otherwise, we are maintaining this step.

Ketan Athavale: Okay. So, this INR400 crores-INR500 crores, this is without considering that INR600 crores order?

Dewansh Vasani: Yes. Sir, it is done from the next year. Ketan Athavale: Yes, that is right. Okay, got it. And just one last question. Can you give any update on pending trade receivables?

Dewansh Vasani: Trade receivables are almost in cycles. And they are all realizable on the regular basis as per their due dates.

Ketan Athavale: Okay. Thank you, sir. Dewansh Vasani: Yes.

Moderator: Thank you so much. The next question is from the line of Hemant Shah, who is an individual investor. Please go ahead.

Hemant Shah: Thank you for the opportunity. First of all, Hemant bhai, our result was a bit down this time, Q1 and H1 both. So, what were the major factors behind that?

Dewansh Vasani: Sir, can you please come again?

Hemant Shah: I am saying that our result was a bit down. From around INR14 crores, we came around INR13 crores. EBITDA also came around INR3.25 crores. PAT also came around INR2 crores. It came down by INR20 lakhs-INR25 lakhs. And the margin was also a bit squeezed. So, what was the major factor? In the performance of Q2 and in H1 also, our performance was also a bit subdued. So, what was the major reason for that?

Dewansh Vasani: Sir, the thing is that sometimes we have orders, but the manufacturer is late in getting the goods from the side. Our goods are being made at least on the 22 sites. At some places, we get stuck in the queue and we have to sell all the goods at once. So, we have to wait. We keep the

Page 8 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

goods in the warehouse, but the goods are not getting exported. So, the result is a bit behind. There is no other reason. And there is also this in the market these days, sir. If there is no advance money at the time of work, then we are a little late in making the goods.

Hemant Shah:

Okay. So, sir, what is the scenario of H2 now? The remainder that is left is FY ‘24. So, how much order booking do we have in our hands? And we will be able to cross our last year's top line. Last year, we had a profit of around INR72 crores and a profit of around INR6.5 crores. So, if H2 is better than that, then our performance will be better than last year. So, what is the situation?

Dewansh Vasani:

Sir, it will be much better. We have an order of at least INR15 crores in the pipeline, which is already on hand.

Hemant Shah:

Okay.

Dewansh Vasani:

And as the year progresses, we will be better than last year.

Hemant Shah:

Okay, sir. And the vertical of Nutraceutical that we have started, what strategy are we adopting in that? Are we selling it in the brand of Vaishali after getting it done on contract manufacturing? Or are we thinking about our own manufacturing in that product? So, what is the scenario in that?

Dewansh Vasani:

Sir, we are selling all these products under the brand name Vaishali. That is our strategy. Now, we are planning to launch it in the domestic market as well. In the marketplace, we have a reputable brand called Vaishali Pharma. We have progressed beyond that brand, and it is also available in the marketplace. Gradually, we will add more products to it. So, we are expanding domestically and conducting business from both online and offline channels. We are supplying domestically and internationally. However, the approval process for exports takes some time due to the unique taste and requirements of our products. It involves detailed procedures. Despite some time, delays, our progress is steady.

Hemant Shah:

Okay. So, we are not doing manufacturing yet. We are getting contract manufacturing done from our vendors?

Dewansh Vasani:

Yes, sir. I think you had answered this before. That two years, two years down the line, we are planning to acquire this.

Hemant Shah:

Yes, yes. Correct, correct. So, it is on the same model as the other API.

Dewansh Vasani:

Yes, sir. It is on contract manufacturing.

Hemant Shah: Okay, okay. And, sir, what will be our major focus? On vertical? On API? On formulation? Nutraceutical?

Dewansh Vasani:

Sir, our major are formulations and Nutraceutical.

Hemant Shah:

Okay, okay. And, sir, can you tell us the margin profile? Let's say, how much percentage EBITDA is being made in the API, how much is being made in the formulation, and how

Page 9 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

much are we expecting from the Nutraceutical? Because, you said that there is a chance that your margin will improve a little. So, I am just understanding, what are the chances that your margin will improve from the vertical?

Dewansh Vasani: Sir, the maximum margin is obtained from the formulation. It is a long-term process. You have to register, and then it has to start in the country. It takes three to four years to start.

Hemant Shah: Okay. Dewansh Vasani: Because there is less competition. Because we have to register. Hemant Shah: Okay. Dewansh Vasani: So, the maximum margin is in that. The more the business grows, the more the margin increases. In the rest of the items, there is not much margin in the API, but the maximum margin is in the formulation, and it can have a margin of 15% to 40%. So, the ratio of our margin, the bottom line is increasing because of the formulation.

Hemant Shah: Okay. And what will be the profile of the Nutraceutical? Will it be better than the API? Dewansh Vasani: Sir, for us, the Nutra and pharma are in the same category. Hemant Shah: Okay. Dewansh Vasani: So, the margin remains the same. Hemant Shah: Got it. And which country will have the most exposure? We are exporting to about 30 to 35 countries. Dewansh Vasani: Africa. In Africa region. Hemant Shah: In Africa. And in particular, which country will have the most exposure? Dewansh Vasani: Sir, I cannot tell you in the story because there are so many people in our competition. Hemant Shah: No problem. No issue, no issue sir. There is no problem. Africa is our major focus area. Dewansh Vasani: I just said that. There is no problem. Hemant Shah: And in Vietnam and Myanmar, we have offices in Vietnam. So how are we expanding there? Dewansh Vasani: Sir, we have done a lot of planning there. But sir, we have not succeeded yet. We have done it in Kenya as well. But we have not succeeded in Vietnam. But we have succeeded in Myanmar. Hemant Shah: Okay, okay. So if we continue like this, will Africa still be the primary? Then India will come a little bit or will the scenario change? Dewansh Vasani: Yes. Sir, we started primarily in the African region. Gradually, sir, we have in the Gulf, LATAM, CIS, Southeast Asia. And gradually we have increased. In the starting, sir, we started

Page 10 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

from three, four countries. From one country, two countries, four countries. Then gradually, sir, as the sales started coming, and as good factories started being established, then we started increasing in other standards.

Hemant Shah: That's right. So now, as Africa is getting the most revenue, it will continue. And what scenario are we thinking in India now? Will India overtake Africa? Or will Africa still be our primary market?

Dewansh Vasani: Sir, the primary market can be counted as the African region. And as soon as the down the line, as soon as the Luliconazole is ongoing, comes in the pipeline, then the European and Latin American countries will also play a major role in this.

Hemant Shah:

Okay, okay, sir. Thank you, thank you so much. All the best, sir.

Dewansh Vasani:

Thank you, sir.

Moderator: Thank you. The next question is from the line of Agam Shah, who's an individual investor. Please go ahead.

Agam Shah: Thank you for the opportunity. Quick question. You said, I think I missed your initial remarks and I joined in late. So, pardon me. Can you give your guidance for broad, how are we seeing coming in two to three years down the line in terms of top line in EBITDA margins? And any capex you require for reaching that number?

Dewansh Vasani: Sir, gradually we are experiencing an annual growth rate of 18% to 20%. We expect minimal changes in that trend. However, there is a possibility of slight increase or a normal variation. Other companies have started projecting a growth rate ranging from 18% to 25%. Regarding the requirements or needs you have mentioned, we have made arrangements to address them. This is focused on facilitating growth, and currently, we do not require additional capital or capacity.

As for the company's future plans, sir, in the next two to three years, we are considering acquiring a manufacturing facility. This strategic move would enable us to expand vertically, and currently, we are operating under an asset-light model. Nevertheless, even today, we anticipate facing substantial demand, and we are confident in our ability to fulfill it through our manufacturing unit.

Agam Shah: Okay. but in terms of number, can you tell the manufacturing unit that any target will be so want to make revenue by this year or anything, if you would like to share?

Dewansh Vasani: Sir If we compare it to the previous year, the company is currently experiencing a 20% growth. We are closely monitoring the company’s progress this year. So we are looking at 20% growth now.

Agam Shah: Okay. by FY'26 or '27 anything in mind should it double?

Page 11 of 12

Vaishali Pharma Limited November 23, 2023

==> picture [65 x 59] intentionally omitted <==

Dewansh Vasani:

As Sir mentioned, just like Atul Sir shared, the goal of achieving INR500 crores in five years is a dream. They believe it will be accomplished, and they have also explained the planning and approach. Hopefully, growth will align with their expectations.

Agam Shah:

Okay and the margin will remain the same, which means it will increase?

Dewansh Vasani:

Sir, the margin in this case grows just like repeated orders or increased expectations. The advantage of having your own brand on top of this is that the margin doesn’t decrease with brand volume; instead, it increases.

Agam Shah:

Okay, okay. Thank you, sir.

Dewansh Vasani:

Thank you.

Moderator: Thank you. As there are no further questions. I would now like to hand the conference over to Ms. Chandani Chande for closing comments.

Chandani Chande: Thank you everyone for joining the conference call of Vaishali Pharma Limited. If you have any query, you can write to us at research at direct@kirinadvisors.com. Once again, thank you for joining the conference.

Moderator: Thank you. on behalf of Kirin Advisors, that concludes this conference. Thank you for joining us and you may now disconnect your lines.

Dewansh Vasani:

Thank you.

Page 12 of 12